PRECYCLE: multicenter, randomized phase IV intergroup trial to evaluate the impact of eHealth-based patient-reported outcome (PRO) assessment on quality of life in patients with hormone receptor positive, HER2 negative locally advanced or metastatic breast cancer treated with palbociclib and an aromatase inhibitor or palbociclib and fulvestrant

Peer Review reports

Original Submission
12 Apr 2021	Submitted	Original manuscript
30 Jun 2021	Reviewed	Reviewer Report - Alexander Gough
19 Aug 2021	Reviewed	Reviewer Report - Samantha Cruz Rivera
29 Sep 2021	Reviewed	Reviewer Report - Jamie Stobo
24 Jan 2022	Author responded	Author comments - Tom Degenhardt
Resubmission - Version 2
24 Jan 2022	Submitted	Manuscript version 2
1 Mar 2022	Reviewed	Reviewer Report - Alexander Gough
14 Mar 2022	Reviewed	Reviewer Report - Jamie Stobo
10 Oct 2022	Author responded	Author comments - Tom Degenhardt
Resubmission - Version 3
10 Oct 2022	Submitted	Manuscript version 3
27 Oct 2022	Reviewed	Reviewer Report - Alexander Gough
3 Nov 2022	Reviewed	Reviewer Report - Jamie Stobo
18 Jan 2023	Author responded	Author comments - Tom Degenhardt
Resubmission - Version 4
18 Jan 2023	Submitted	Manuscript version 4
30 Jan 2023	Reviewed	Reviewer Report - Alexander Gough
Resubmission - Version 5
	Submitted	Manuscript version 5
Publishing
11 Apr 2023	Editorially accepted
17 May 2023	Article published	10.1186/s13063-023-07306-z

Back to article page